1. Home
  2. PEBO vs DMAC Comparison

PEBO vs DMAC Comparison

Compare PEBO & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PEBO
  • DMAC
  • Stock Information
  • Founded
  • PEBO 1902
  • DMAC 2000
  • Country
  • PEBO United States
  • DMAC United States
  • Employees
  • PEBO N/A
  • DMAC N/A
  • Industry
  • PEBO Major Banks
  • DMAC Biotechnology: Pharmaceutical Preparations
  • Sector
  • PEBO Finance
  • DMAC Health Care
  • Exchange
  • PEBO Nasdaq
  • DMAC Nasdaq
  • Market Cap
  • PEBO N/A
  • DMAC 178.0M
  • IPO Year
  • PEBO N/A
  • DMAC N/A
  • Fundamental
  • Price
  • PEBO $32.10
  • DMAC $3.76
  • Analyst Decision
  • PEBO Buy
  • DMAC Strong Buy
  • Analyst Count
  • PEBO 6
  • DMAC 2
  • Target Price
  • PEBO $36.67
  • DMAC $8.00
  • AVG Volume (30 Days)
  • PEBO 159.5K
  • DMAC 307.4K
  • Earning Date
  • PEBO 07-22-2025
  • DMAC 08-06-2025
  • Dividend Yield
  • PEBO 5.11%
  • DMAC N/A
  • EPS Growth
  • PEBO N/A
  • DMAC N/A
  • EPS
  • PEBO 3.15
  • DMAC N/A
  • Revenue
  • PEBO $561,241,000.00
  • DMAC N/A
  • Revenue This Year
  • PEBO N/A
  • DMAC N/A
  • Revenue Next Year
  • PEBO $3.67
  • DMAC N/A
  • P/E Ratio
  • PEBO $10.19
  • DMAC N/A
  • Revenue Growth
  • PEBO 12.39
  • DMAC N/A
  • 52 Week Low
  • PEBO $26.21
  • DMAC $2.80
  • 52 Week High
  • PEBO $37.07
  • DMAC $6.82
  • Technical
  • Relative Strength Index (RSI)
  • PEBO 72.10
  • DMAC 47.18
  • Support Level
  • PEBO $30.37
  • DMAC $3.48
  • Resistance Level
  • PEBO $30.41
  • DMAC $3.99
  • Average True Range (ATR)
  • PEBO 0.64
  • DMAC 0.32
  • MACD
  • PEBO 0.28
  • DMAC -0.00
  • Stochastic Oscillator
  • PEBO 94.41
  • DMAC 41.01

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: